CD19 Antibody [H7K12] | Primary Antibodies

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:1000 IP1:30 IHC1:1000 IF1:50 FCM1:500

Application
WB, IP, IHC, IF, FCM

Reactivity
Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
61 kDa 60-120 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CD19 Antibody [H7K12] detects endogenous levels of total CD19 protein.

Clone
H7K12

Synonym(s)
CD19, B-lymphocyte antigen CD19, Differentiation antigen CD19, Cd19

Background
CD19 is a type I transmembrane immunoglobulin-superfamily receptor that is expressed from early B‑cell precursors through mature B cells and acts as the principal signaling co-receptor that tunes B‑cell antigen receptor (BCR) sensitivity, integrating complement-tagged antigen recognition with intracellular kinase cascades that govern B‑cell activation, tolerance, and survival. The extracellular region contains paired Ig-like domains that assemble with CD21 and CD81 in a multimeric coreceptor complex, positioning CD19 close to the BCR and complement receptor to sense antigen–C3d conjugates at the cell surface, while the cytoplasmic tail carries multiple tyrosine-based motifs that serve as docking sites for Src-family kinases and the p85 regulatory subunit of PI3K. Antigen engagement of the BCR in the presence of CD19–CD21–CD81 co-ligation triggers phosphorylation of CD19 cytoplasmic tyrosines by Src kinases such as Lyn, creating binding sites for PI3K and other adaptors; this leads to robust generation of PtdIns(3,4,5)P3, recruitment and activation of BTK and PLCγ2, and amplification of calcium flux and downstream MAPK and NF‑κB signaling, thereby lowering the threshold for B‑cell activation and promoting proliferation, differentiation, and antibody production after antigen encounter. CD19 also supports tonic, receptor-independent PI3K signaling that is needed to maintain B‑cell survival and homeostasis, and reduced CD19 expression or function impairs germinal center formation, marginal zone B‑cell development, and serum immunoglobulin levels, whereas CD19 overexpression drives hyper-responsiveness and breaks of tolerance, establishing CD19 as a molecular rheostat for intrinsic BCR signaling strength. Basic juxtamembrane segment of the CD19 cytoplasmic tail binds PtdIns(4,5)P2 in the inner leaflet; loss of the 5‑phosphatase INPP5K increases PtdIns(4,5)P2 abundance, promotes a constitutively “open” CD19 conformation, sustains PI3K recruitment and signaling, and leads to impaired B‑cell development with hypogammaglobulinemia.

Background

CD19 is a type I transmembrane immunoglobulin-superfamily receptor that is expressed from early B‑cell precursors through mature B cells and acts as the principal signaling co-receptor that tunes B‑cell antigen receptor (BCR) sensitivity, integrating complement-tagged antigen recognition with intracellular kinase cascades that govern B‑cell activation, tolerance, and survival. The extracellular region contains paired Ig-like domains that assemble with CD21 and CD81 in a multimeric coreceptor complex, positioning CD19 close to the BCR and complement receptor to sense antigen–C3d conjugates at the cell surface, while the cytoplasmic tail carries multiple tyrosine-based motifs that serve as docking sites for Src-family kinases and the p85 regulatory subunit of PI3K. Antigen engagement of the BCR in the presence of CD19–CD21–CD81 co-ligation triggers phosphorylation of CD19 cytoplasmic tyrosines by Src kinases such as Lyn, creating binding sites for PI3K and other adaptors; this leads to robust generation of PtdIns(3,4,5)P3, recruitment and activation of BTK and PLCγ2, and amplification of calcium flux and downstream MAPK and NF‑κB signaling, thereby lowering the threshold for B‑cell activation and promoting proliferation, differentiation, and antibody production after antigen encounter. CD19 also supports tonic, receptor-independent PI3K signaling that is needed to maintain B‑cell survival and homeostasis, and reduced CD19 expression or function impairs germinal center formation, marginal zone B‑cell development, and serum immunoglobulin levels, whereas CD19 overexpression drives hyper-responsiveness and breaks of tolerance, establishing CD19 as a molecular rheostat for intrinsic BCR signaling strength. Basic juxtamembrane segment of the CD19 cytoplasmic tail binds PtdIns(4,5)P2 in the inner leaflet; loss of the 5‑phosphatase INPP5K increases PtdIns(4,5)P2 abundance, promotes a constitutively “open” CD19 conformation, sustains PI3K recruitment and signaling, and leads to impaired B‑cell development with hypogammaglobulinemia.

References
https://pubmed.ncbi.nlm.nih.gov/41033873/ https://pubmed.ncbi.nlm.nih.gov/25755168/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%